美国 · SEC FORM 4
Immunovant, Inc.
IMVT · Nasdaq · CIK 0001764013 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
54 同一窗口内观察到的 Form 4 交易行
39 sales · 15 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-12 · Roivant Sciences Ltd..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 17,416,613
- 上期报告
- 17,253,948
- 日均成交量
- 1,805,887
- 回补天数
- 9.6
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-12 | Roivant Sciences Ltd. | 买入 (P) | Common Stock, $0.0001 par value per share | 16,666,666 | USD 21.00 | USD 349,999,986 | SEC 申报 ↗ |
| 2025-01-13 | Roivant Sciences Ltd. | 买入 (P) | Common Stock, $0.0001 par value per share | 16,845,010 | USD 20.00 | USD 336,900,200 | SEC 申报 ↗ |
| 2023-10-02 | Roivant Sciences Ltd. | 买入 (P) | Common Stock, $0.0001 par value per share | 1,526,316 | USD 38.00 | USD 58,000,008 | SEC 申报 ↗ |
| 2022-10-06 | Roivant Sciences Ltd. | 买入 (P) | Common Stock, $0.0001 par value per share | 416,667 | USD 6.00 | USD 2,500,002 | SEC 申报 ↗ |
| 2022-09-30 | Pande Atul | 买入 (P) | Common Stock | 15,000 | USD 5.60 | USD 84,000 | SEC 申报 ↗ |
| 2022-09-29 | Torti Frank | 买入 (P) | Common Stock | 20,000 | USD 5.81 | USD 116,200 | SEC 申报 ↗ |
| 2021-08-27 | Hughes Douglas J. | 买入 (P) | Common Stock | 18,247 | USD 8.24 | USD 150,355 | SEC 申报 ↗ |
| 2021-08-20 | MIGAUSKY GEORGE V | 买入 (P) | Common Stock | 7,000 | USD 7.65 | USD 53,550 | SEC 申报 ↗ |
| 2021-08-13 | Pande Atul | 买入 (P) | Common Stock | 5,000 | USD 7.98 | USD 39,900 | SEC 申报 ↗ |
| 2021-08-10 | Fromkin Andrew J. | 买入 (P) | Common Stock | 5,500 | USD 7.90 | USD 43,450 | SEC 申报 ↗ |
| 2020-09-11 | Butchko Julia G. | 买入 (P) | Common Stock | 5,000 | USD 38.17 | USD 190,850 | SEC 申报 ↗ |
| 2020-09-04 | Roivant Sciences Ltd. | 买入 (P) | Common Stock, $0.0001 par value per share | 380,000 | USD 33.00 | USD 12,540,000 | SEC 申报 ↗ |
| 2020-04-16 | Roivant Sciences Ltd. | 买入 (P) | Common Stock, $0.0001 par value per share | 1,034,483 | USD 14.50 | USD 15,000,004 | SEC 申报 ↗ |
Form 4 申报证据
91 transaction lines in the latest 365-day window; 382 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Van Tuyl Christopher | 卖出 (S) | Common Stock | 1,327 | USD 32.06 | USD 42,544 | SEC 申报 ↗ |
| 2026-10-07 | Stout Jay S | 卖出 (S) | Common Stock | 3,809 | USD 32.06 | USD 122,117 | SEC 申报 ↗ |
| 2026-10-07 | Gloria Melanie | 卖出 (S) | Common Stock | 2,241 | USD 32.06 | USD 71,846 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Van Tuyl Christopher | 卖出 (S) | Common Stock | 1,327 | USD 32.06 | USD 42,544 | SEC 申报 ↗ |
| 2026-10-07 | Stout Jay S | 卖出 (S) | Common Stock | 3,809 | USD 32.06 | USD 122,117 | SEC 申报 ↗ |
| 2026-10-07 | Gloria Melanie | 卖出 (S) | Common Stock | 2,241 | USD 32.06 | USD 71,846 | SEC 申报 ↗ |
| 2026-10-02 | Venker Eric | 卖出 (S) | Common Stock | 3,506 | USD 34.11 | USD 119,590 | SEC 申报 ↗ |
| 2026-10-01 | Venker Eric | 期权行权/转换 (M) | Common Stock | 92,187 | USD 14.46 | USD 1,333,024 | SEC 申报 ↗ |
| 2026-10-01 | Venker Eric | D (D) | Common Stock | 85,886 | USD 33.65 | USD 2,890,064 | SEC 申报 ↗ |
| 2026-09-23 | Van Tuyl Christopher | 卖出 (S) | Common Stock | 2,846 | USD 36.36 | USD 103,481 | SEC 申报 ↗ |
| 2026-08-28 | Pande Atul | 卖出 (S) | Common Stock | 1,500 | USD 43.27 | USD 64,905 | SEC 申报 ↗ |
| 2026-08-28 | Pande Atul | 期权行权/转换 (M) | Common Stock | 1,500 | USD 8.43 | USD 12,645 | SEC 申报 ↗ |
| 2026-08-20 | Gloria Melanie | 卖出 (S) | Common Stock | 3,056 | USD 44.16 | USD 134,953 | SEC 申报 ↗ |
| 2026-07-24 | Pande Atul | 卖出 (S) | Common Stock | 1,500 | USD 39.80 | USD 59,700 | SEC 申报 ↗ |
| 2026-07-24 | Pande Atul | 期权行权/转换 (M) | Common Stock | 1,500 | USD 8.43 | USD 12,645 | SEC 申报 ↗ |
| 2026-07-23 | Stout Jay S | 卖出 (S) | Common Stock | 2,857 | USD 38.69 | USD 110,537 | SEC 申报 ↗ |
| 2026-07-23 | Girao Tiago | 卖出 (S) | Common Stock | 6,798 | USD 38.69 | USD 263,015 | SEC 申报 ↗ |
| 2026-07-08 | Van Tuyl Christopher | 卖出 (S) | Common Stock | 1,206 | USD 39.55 | USD 47,702 | SEC 申报 ↗ |
| 2026-07-08 | Stout Jay S | 卖出 (S) | Common Stock | 3,487 | USD 39.55 | USD 137,925 | SEC 申报 ↗ |
| 2026-07-08 | Gloria Melanie | 卖出 (S) | Common Stock | 2,036 | USD 39.55 | USD 80,532 | SEC 申报 ↗ |
| 2026-07-02 | Venker Eric | 卖出 (S) | Common Stock | 3,092 | USD 38.48 | USD 118,980 | SEC 申报 ↗ |
| 2026-07-01 | Venker Eric | 期权行权/转换 (M) | Common Stock | 92,188 | USD 14.46 | USD 1,333,038 | SEC 申报 ↗ |
| 2026-07-01 | Venker Eric | D (D) | Common Stock | 86,629 | USD 38.14 | USD 3,304,030 | SEC 申报 ↗ |
| 2026-06-26 | Van Tuyl Christopher | 卖出 (S) | Common Stock | 17,824 | USD 38.31 | USD 682,887 | SEC 申报 ↗ |
| 2026-06-26 | Van Tuyl Christopher | 期权行权/转换 (M) | Common Stock | 17,824 | USD 15.20 | USD 270,925 | SEC 申报 ↗ |
| 2026-06-26 | Stout Jay S | 卖出 (S) | Common Stock | 40,000 | USD 38.31 | USD 1,532,309 | SEC 申报 ↗ |
| 2026-06-26 | Pande Atul | 卖出 (S) | Common Stock | 1,500 | USD 38.01 | USD 57,015 | SEC 申报 ↗ |
| 2026-06-26 | Pande Atul | 期权行权/转换 (M) | Common Stock | 1,500 | USD 8.43 | USD 12,645 | SEC 申报 ↗ |
| 2026-06-26 | Gloria Melanie | 卖出 (S) | Common Stock | 17,714 | USD 38.31 | USD 678,604 | SEC 申报 ↗ |
| 2026-06-26 | Girao Tiago | 卖出 (S) | Common Stock | 10,000 | USD 38.46 | USD 384,600 | SEC 申报 ↗ |
| 2026-06-26 | Girao Tiago | 期权行权/转换 (M) | Common Stock | 10,000 | USD 15.90 | USD 159,000 | SEC 申报 ↗ |
| 2026-06-18 | Van Tuyl Christopher | 卖出 (S) | Common Stock | 2,634 | USD 35.39 | USD 93,217 | SEC 申报 ↗ |
| 2026-06-15 | Pande Atul | 卖出 (S) | Common Stock | 1,500 | USD 34.02 | USD 51,030 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IMVT |
| CIK | 0001764013 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 382 transaction lines from 2020-04-16 to 2026-10-07 13 P purchase lines · 257 S sale lines · 112 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.